Successful Tocilizumab Treatment In A Patient With Human Herpesvirus 8-Positive And Human Immunodeficiency Virus-Negative Multicentric Castleman's Disease Of Plasma Cell Type Nonresponsive To Rituximab-CVP Therapy

APMIS

Volumn 121, Issue 7, 2013, Pages 668-674

  Muzes, Györgyi ^a   Sipos, Ferenc ^a   Csomor, Judit ^a   Sréter, Lídia ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Human herpesvirus 8; Interleukin 6; Multicentric Castleman's disease; Rituximab; Tocilizumab

Indexed keywords

RITUXIMAB; TOCILIZUMAB;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FATIGUE; FEMALE; FEVER; HEPATOSPLENOMEGALY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MICROCYTIC ANEMIA; PLASMA CELL; PLASMACYTOSIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AZATHIOPRINE; DNA, VIRAL; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HIV SERONEGATIVITY; HUMANS; LYMPH NODES; TREATMENT OUTCOME;

EID: 84879500926     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12029     Document Type: Article

References (16)

1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 1954;251:396-400.
2. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998;128:657-62.
3. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005;129:3-17.
4. Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol 2012;3:73.
5. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978;69:86-90.
6. Gessain A, Sudaka A, Brière J, Fouchard N, Nicola MA, Rio B, et al. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 1996;87:414-6.
7. Kojima M, Nakamura S, Nishikawa M, Itoh H, Miyawaki S, Masawa N. Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases. Pathol Res Pract 2005;201:325-32.
8. Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol 2005;6:255-66.
9. El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist 2011;16:497-511.
10. Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007;147:836-9.
11. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
12. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
13. Yamasaki S, Iino T, Nakamura M, Henzan H, Ohshima K, Kikuchi M, et al. Detection of human herpesvirus-8 in peripheral blood mononuclear cells from adult Japanese patients with multicentric Castleman's disease. Br J Haematol 2003;120:471-7.
14. Levi JE, Nascimento MC, Sumita LM, de Souza VA, Freire WS, Mayaud P, et al. Non-detection of human herpesvirus 8 (HHV-8) DNA in HHV-8-seropositive blood donors from three Brazilian regions. PLoS ONE 2011;6:e23546.
15. Martró E, Cannon MJ, Dollard SC, Spira TJ, Laney AS, Ou CY, et al. Evidence for both lytic replication and tightly regulated human herpesvirus 8 latency in circulating mononuclear cells, with virus loads frequently below common thresholds of detection. J Virol 2004;78:11707-14.
16. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. IL-6 plays an essential role in multi-factors associated hepcidin regulation: anti-IL-6R Ab therapy improve inflammatory anemia in multicentric Castleman's disease (MCD) and rheumatoid arthritis (RA) patients. Clin Immunol 2010;135:S69-70.